vs
Crexendo, Inc.（CXDO）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Crexendo, Inc.的1.1倍（$19.6M vs $18.1M），Crexendo, Inc.净利率更高（6.7% vs -177.4%，领先184.2%），Crexendo, Inc.同比增速更快（11.2% vs -11.5%），过去两年Crexendo, Inc.的营收复合增速更高（12.4% vs -12.2%）
Crexendo, Inc.是一家总部位于美国的云通信技术供应商，主要面向北美市场的中小企业提供统一通信即服务、呼叫中心解决方案、商业VoIP服务及相关协同办公工具。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CXDO vs LAB — 直观对比
营收规模更大
LAB
是对方的1.1倍
$18.1M
营收增速更快
CXDO
高出22.7%
-11.5%
净利率更高
CXDO
高出184.2%
-177.4%
两年增速更快
CXDO
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.1M | $19.6M |
| 净利润 | $1.2M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 6.3% | -168.5% |
| 净利率 | 6.7% | -177.4% |
| 营收同比 | 11.2% | -11.5% |
| 净利润同比 | 140.2% | -28.8% |
| 每股收益（稀释后） | $0.03 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXDOLAB
| Q4 25 | $18.1M | — | ||
| Q3 25 | $17.5M | $19.6M | ||
| Q2 25 | $16.6M | $21.8M | ||
| Q1 25 | $16.1M | $40.8M | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $15.6M | $22.1M | ||
| Q2 24 | $14.7M | $22.5M | ||
| Q1 24 | $14.3M | $45.5M |
净利润CXDOLAB
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | $-34.7M | ||
| Q2 25 | $1.2M | $-33.5M | ||
| Q1 25 | $1.2M | $-26.0M | ||
| Q4 24 | $507.0K | — | ||
| Q3 24 | $148.0K | $-26.9M | ||
| Q2 24 | $588.0K | $-45.7M | ||
| Q1 24 | $434.0K | $-32.2M |
毛利率CXDOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率CXDOLAB
| Q4 25 | 6.3% | — | ||
| Q3 25 | 7.5% | -168.5% | ||
| Q2 25 | 6.7% | -118.1% | ||
| Q1 25 | 7.2% | -80.8% | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 0.9% | -120.9% | ||
| Q2 24 | 3.9% | -134.5% | ||
| Q1 24 | 3.4% | -132.2% |
净利率CXDOLAB
| Q4 25 | 6.7% | — | ||
| Q3 25 | 8.3% | -177.4% | ||
| Q2 25 | 7.4% | -153.7% | ||
| Q1 25 | 7.3% | -63.8% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 0.9% | -122.0% | ||
| Q2 24 | 4.0% | -203.3% | ||
| Q1 24 | 3.0% | -70.6% |
每股收益（稀释后）CXDOLAB
| Q4 25 | $0.03 | — | ||
| Q3 25 | $0.05 | $-0.09 | ||
| Q2 25 | $0.04 | $-0.09 | ||
| Q1 25 | $0.04 | $-0.07 | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.00 | $-0.07 | ||
| Q2 24 | $0.02 | $-0.12 | ||
| Q1 24 | $0.01 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $114.0K | — |
| 股东权益账面价值 | $63.8M | $399.7M |
| 总资产 | $77.7M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资CXDOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务CXDOLAB
| Q4 25 | $114.0K | — | ||
| Q3 25 | $236.0K | — | ||
| Q2 25 | $356.0K | — | ||
| Q1 25 | $475.0K | — | ||
| Q4 24 | $592.0K | — | ||
| Q3 24 | $709.0K | $55.2M | ||
| Q2 24 | $823.0K | $55.1M | ||
| Q1 24 | $937.0K | $55.0M |
股东权益CXDOLAB
| Q4 25 | $63.8M | — | ||
| Q3 25 | $61.3M | $399.7M | ||
| Q2 25 | $58.3M | $424.5M | ||
| Q1 25 | $55.2M | $454.6M | ||
| Q4 24 | $51.4M | — | ||
| Q3 24 | $49.5M | $489.3M | ||
| Q2 24 | $48.2M | $510.3M | ||
| Q1 24 | $46.8M | $577.3M |
总资产CXDOLAB
| Q4 25 | $77.7M | — | ||
| Q3 25 | $76.0M | $539.6M | ||
| Q2 25 | $71.4M | $557.0M | ||
| Q1 25 | $67.4M | $579.6M | ||
| Q4 24 | $64.9M | — | ||
| Q3 24 | $62.3M | $681.5M | ||
| Q2 24 | $59.6M | $708.7M | ||
| Q1 24 | $57.5M | $777.7M |
负债/权益比CXDOLAB
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | 0.11× | ||
| Q2 24 | 0.02× | 0.11× | ||
| Q1 24 | 0.02× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | 0.0% | 4.5% |
| 现金转化率经营现金流/净利润 | 1.93× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CXDOLAB
| Q4 25 | $2.3M | — | ||
| Q3 25 | $4.4M | $-22.2M | ||
| Q2 25 | $1.3M | $-20.7M | ||
| Q1 25 | $1.2M | $-30.3M | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $1.6M | $-27.9M | ||
| Q2 24 | $2.7M | $-39.0M | ||
| Q1 24 | $-166.0K | $-62.5M |
自由现金流CXDOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | $1.3M | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率CXDOLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | 7.7% | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度CXDOLAB
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 0.1% | 8.7% | ||
| Q1 25 | 0.0% | 12.4% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | 10.2% | ||
| Q2 24 | 0.0% | 8.6% | ||
| Q1 24 | 0.0% | 1.7% |
现金转化率CXDOLAB
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | — | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
